GET DAILY SIGNALSWhy Is Annexon Biosciences (ANNX) Stock Down -3.99% Today?
Key Takeaways
- ANNX fell about 3.99% to roughly $3.85, down from the prior session's close of $4.01.
- The decline came despite a bullish analyst note, as investors locked in profits following Monday's sharp rally.
- Shares had surged roughly 17.6% the prior session on positive FORWARD study data for its lead Guillain-Barré syndrome candidate.
- H.C. Wainwright raised its price target to $25 from $14 while reiterating a Buy rating.
- Traders are watching the upcoming tanruprubart BLA submission and the Q4 2026 ARCHER II readout.
Opening Summary
Annexon Biosciences (ANNX), a clinical-stage biopharmaceutical company developing therapies targeting the classical complement pathway for autoimmune, neurodegenerative, and ophthalmic diseases, pulled back in Tuesday's session. The stock traded down roughly 3.99% to about $3.85, compared with a prior close of $4.01. The move marks a classic profit-taking pullback after a sharp single-day advance, with the retreat occurring even as analysts raised their outlooks for the company's Guillain-Barré syndrome (GBS) program and its late-stage pipeline.
Profit-Taking Follows a Sharp Rally
The primary driver behind Tuesday's decline was a round of profit-taking after ANNX surged approximately 17.6% in the prior session. That rally was fueled by newly reported FORWARD study results, in which all ten enrolled U.S. and European GBS patients showed early muscle-strength improvements and reduced disability within days of a single infusion of tanruprubart, the company's lead candidate. The data reinforced earlier Phase 3 and real-world evidence, strengthening the case for what could become the first approved targeted therapy for Guillain-Barré syndrome.
After such a rapid upward move, it is common for short-term traders and some institutional investors to take gains off the table, even when the underlying fundamentals appear unchanged. The pullback on Tuesday reflects that dynamic rather than any deterioration in the company's clinical or regulatory story.
Bullish Analyst Upgrade Fails to Halt the Slide
Adding context to the session, H.C. Wainwright raised its price target on ANNX to $25 from $14 while maintaining a Buy rating. The firm cited increased confidence in the approvability of tanruprubart for GBS, highlighting the planned Biologics License Application (BLA) submission as well as the fourth-quarter 2026 ARCHER II readout for vonaprument in geographic atrophy.
The upgrade, however, did not prevent the stock's decline, underscoring that the day's move was driven more by positioning and momentum than by a reassessment of the company's long-term value. The broader analyst community maintains a consensus Strong Buy rating, with targets ranging from $7 to $27, according to market data.
Market Context and Trading Activity
The pullback in ANNX unfolded against a backdrop of elevated trading volume. Monday's rally occurred on turnover well above the stock's typical pace, and Tuesday's session saw continued active trading as investors digested the analyst commentary and locked in profits. Clinical-stage biotechnology names remain sensitive to shifts in risk appetite, and individual stock moves in this segment often diverge from broader equity indices, which were comparatively stable during the period.
Despite the recent weakness, the stock has still retraced only a portion of Monday's gains, suggesting the intermediate trend remains intact even as near-term technical resistance near the $4.00 level has capped further upside for now.
What Comes Next for ANNX
Looking ahead, investors will focus on two defined catalysts. First, the company is advancing a BLA submission for tanruprubart in Guillain-Barré syndrome, a milestone that would move the program toward potential U.S. regulatory review. Second, the fourth-quarter 2026 ARCHER II readout for vonaprument in geographic atrophy is expected to provide a key data point on a second major program.
Risks remain typical for a clinical-stage biotech. The company reported a wider-than-expected second-quarter loss and continues to burn cash as it advances its pipeline, though it maintains a solid balance sheet with more cash than debt. The stock has also declined significantly over the trailing six-month period, and investor sentiment could remain volatile around upcoming clinical and regulatory events.
Trending AI Robots
Traders seeking a data-driven edge can explore Tickeron's Trending AI Robots page. Tickeron offers hundreds of AI-powered trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this curated section. The bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing users to find approaches that match their own objectives. Discover which strategies are leading the market today.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for ANNX turns negative, indicating new downward trend
ANNX saw its Momentum Indicator move below the 0 level on October 12, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 80 similar instances where the indicator turned negative. In 74 of the 80 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANNX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for ANNX entered a downward trend on October 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ANNX's RSI Indicator exited the oversold zone, 32 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for ANNX just turned positive on October 19, 2026. Looking at past instances where ANNX's MACD turned positive, the stock continued to rise in 39 of 45 cases over the following month. The odds of a continued upward trend are 87%.
Following a +1.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where ANNX advanced for three days, in 224 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
ANNX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. ANNX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 60 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.086) is normal, around the industry mean (2.978). P/E Ratio (-3.549) is within average values for comparable stocks, (-0.692). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (134.267) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANNX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain
Industry Biotechnology
Advertisement